Study announces preliminary results of taletrectinib treatment of ROS1 fusion-positive NSCLC trial

Article source: Pharmaceutical Guanlan

The 2021 American Society of Clinical Oncology (ASCO) annual meeting is in progress

As a new generation of TKI drugs, taletrectinib targets ROS1 and NTRK fusion mutations, and has the potential to treat patients who have not been treated with TKI and who have undergone TKI treatment

The poster titled at the ASCO annual meeting is "Preliminary results of the TRUST study: taletrectinib is used in the Phase 2 clinical trial of ROS1 fusion-positive non-small cell lung cancer patients

• Among patients who were not treated with crizotinib (n=15), the objective response rate (ORR) was 93% (14/15), and the disease control rate (DCR) was 93% (14/15);

• Among patients who had received crizotinib treatment (n=5), the objective response rate (ORR) was 60% (3/5); the disease control rate (DCR) was 100% (5/5)

•Taletrectinib has a controllable safety, mainly manifested as gastrointestinal adverse events and reversible AST and ALT elevations

Note: The original text has been deleted